Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%

MT Newswires Live05-28

Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.

Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.

The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.

Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.

The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638654388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 12:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638654388","market":"sg","top_or_hot":-1,"title":"Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PHBBF\">Pharmaron Beijing</a> (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.</p><p>Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.</p><p>The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.</p><p>Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.</p><p>The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-28 12:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PHBBF\">Pharmaron Beijing</a> (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.</p><p>Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.</p><p>The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.</p><p>Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.</p><p>The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638654388","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638654388","pubTimestamp":1779943470,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pharmaron Beijing  plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300759":"康龙化成","BK1141":"生命科学工具和服务","BK0216":"研究试验","03759":"康龙化成","BK1576":"医药外包概念"},"translate_title":"康龙化成拟50亿元投资药品制造项目；股价下跌3%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300759":0.9,"03759":0.9},"content_text":"Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638654388","isCrawlerRequest":true}